## Suresh Senan

### List of Publications by Citations

Source: https://exaly.com/author-pdf/9093829/suresh-senan-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20,855 76 135 377 h-index g-index citations papers 6.71 25,069 398 3.5 ext. citations L-index avg, IF ext. papers

#	Paper	IF	Citations
377	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 630-7	21.7	877
376	Prophylactic cranial irradiation in extensive small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 664-72	59.2	793
375	Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. <i>Lancet, The</i> , <b>2019</b> , 393, 2051-2058	40	764
374	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2016</b> , 27, v1-v27	10.3	590
373	Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 763-72	21.7	489
372	Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 70, 685-92	4	438
371	Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 85, 444-50	4	384
370	Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2013</b> , 24 Suppl 6, vi89-98	10.3	376
369	Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5153-9	2.2	349
368	Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 252-9	4	340
367	Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 802-9	21.7	323
366	Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. <i>Lancet, The</i> , <b>2015</b> , 385, 36-42	40	320
365	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1462-74	10.3	268
364	Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 348-53	4	261
363	PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 953-62	2.2	254
362	An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 346-55	4.9	253
361	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2830-2838	2.2	248

## (2001-2004)

360	Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 60, 1283-90	4	248
359	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical	21.7	247
358	Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 63, 253-60	4	238
357	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1573-88	10.3	225
356	Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 1442-57	4	216
355	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1681-1690	10.3	208
354	Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. <i>Radiation Oncology</i> , <b>2009</b> , 4, 1	4.2	203
353	Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. <i>Journal of</i>	2.2	201
352	Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1543-8	10.3	192
351	Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 276-82	5.3	190
350	European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5301-10	2.2	189
349	Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Journal of Thoracic Oncology, <b>2011</b> , 6, 2036-43	8.9	186
348	Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 71, 139-46	5.3	179
347	The oligometastatic state - separating truth from wishful thinking. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 549-57	19.4	178
346	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1475-84	10.3	174
345	Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 62, 554-60	4	169
344	Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 437-42	5.3	168
343	Multiple "slow" CT scans for incorporating lung tumor mobility in radiotherapy planning.  International Journal of Radiation Oncology Biology Physics, 2001, 51, 932-7	4	167

342	Radiographic changes after lung stereotactic ablative radiotherapy (SABR)can we distinguish recurrence from fibrosis? A systematic review of the literature. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 102, 335-42	5.3	154
341	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 11-17	5.3	149
340	Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. <i>Cancer</i> , <b>2010</b> , 116, 406-14	6.4	149
339	Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 1149-56	4	135
338	Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). <i>Annals of Oncology</i> , <b>2011</b> , 22, 1154-1163	10.3	134
337	Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 93, 122-4	5.3	130
336	Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 101, 240-4	5.3	126
335	Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>1999</b> , 53, 247-55	5.3	124
334	Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. <i>Lung Cancer</i> , <b>2013</b> , 82, 95-102	5.9	123
333	Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 690-6	4	120
332	Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , <b>2012</b> , 12, 305	4.8	118
331	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 860-867	8.9	118
330	Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1081-9	8.9	116
329	Radiological changes after stereotactic radiotherapy for stage I lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1221-8	8.9	113
328	Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 431-6	5.3	111
327	Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2743-2747	10.3	111
326	European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 124, 1-10	5.3	109
325	Tumor location cannot predict the mobility of lung tumors: a 3D analysis of data generated from multiple CT scans. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 56, 348-54	4	106

324	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 146, 223-229	5.3	105
323	Analysis and reduction of 3D systematic and random setup errors during the simulation and treatment of lung cancer patients with CT-based external beam radiotherapy dose planning.  International Journal of Radiation Oncology Biology Physics, 2001, 49, 857-68	4	105
322	Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 101, 250-4	5.3	99
321	Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. Journal of Thoracic Oncology, <b>2019</b> , 14, 2109-2119	8.9	96
320	High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 51-7	5.3	96
319	Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 1121-8	4	95
318	New developments in arc radiation therapy: a review. Cancer Treatment Reviews, 2010, 36, 393-9	14.4	91
317	Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 67, 775-80	4	91
316	Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleuraa single-institution experience with 189 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 43, 511-6	4	89
315	Dosimetric impact of interplay effect on RapidArc lung stereotactic treatment delivery. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 305-11	4	85
314	Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 253-9	4	85
313	Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 54, 999-1006	4	85
312	A critical review of recent developments in radiotherapy for non-small cell lung cancer. <i>Radiation Oncology</i> , <b>2016</b> , 11, 115	4.2	85
311	Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. <i>BMC Cancer</i> , <b>2019</b> , 19, 816	4.8	81
310	Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. Journal of Thoracic Oncology, <b>2012</b> , 7, 1148-54	8.9	81
309	Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1997</b> , 38, 497-506	4	81
308	Predictive factors in radiotherapy for non-small cell lung cancer: present status. <i>Lung Cancer</i> , <b>2001</b> , 31, 43-56	5.9	81
307	Design of clinical trials of radiation combined with antiangiogenic therapy. <i>Oncologist</i> , <b>2007</b> , 12, 465-77	5.7	78

306	A simplified CT-based definition of the lymph node levels in the node negative neck. <i>Radiotherapy and Oncology</i> , <b>1999</b> , 52, 35-42	5.3	78
305	MR-guided Gated Stereotactic Radiation Therapy Delivery for Lung, Adrenal, and Pancreatic Tumors: A Geometric Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 858-866	4	77
304	Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 2052-7	8.9	77
303	Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 974-8	4	76
302	Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for stage I non-small cell lung cancer?. <i>Radiotherapy and Oncology</i> , <b>2002</b> , 63, 151-7	5.3	76
301	Volumetric modulated arc radiotherapy for vestibular schwannomas. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 610-5	4	75
300	Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 114, 138-47	5.3	74
299	Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. <i>Medical Physics</i> , <b>2014</b> , 41, 033502	4.4	73
298	RapidArc planning and delivery in patients with locally advanced head-and-neck cancer undergoing chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 429-35	4	69
297	Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 76, 1106-13	4	69
296	Post-Treatment Mortality After Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 642-651	2.2	68
295	Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 98, 622-631	4	67
294	Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. <i>British Journal of Cancer</i> , <b>2006</b> , 94, 625-30	8.7	67
293	Are multiple CT scans required for planning curative radiotherapy in lung tumors of the lower lobe?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 55, 1394-9	4	67
292	4D imaging for target definition in stereotactic radiotherapy for lung cancer. <i>Acta Oncològica</i> , <b>2006</b> , 45, 966-72	3.2	64
291	Induction treatment before surgery for non-small cell lung cancer. <i>Lung Cancer</i> , <b>2003</b> , 42 Suppl 1, S9-14	5.9	63
290	Fast arc delivery for stereotactic body radiotherapy of vertebral and lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, e137-43	4	62
289	Volumetric modulated arc therapy versus conventional intensity modulated radiation therapy for stereotactic spine radiotherapy: a planning study and early clinical data. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 94, 224-8	5.3	62

## (2007-2019)

288	A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 1086-1094	4	61	
287	Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy?. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, e270-4	21.7	60	
286	Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 117, 44-8	5.3	57	
285	Residual disease at the bronchial stump after curative resection for lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2007</b> , 32, 29-34	3	57	
284	Defining a standard set of patient-centred outcomes for lung cancer. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 852-60	13.6	57	
283	Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 1391-6	4	56	
282	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 325-33	4.9	55	
281	Time trends in target volumes for stage I non-small-cell lung cancer after stereotactic radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 1221-8	4	55	
280	Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. <i>Lung Cancer</i> , <b>2015</b> , 87, 283-9	5.9	53	
279	Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 506-13	4	53	
278	Quality assurance of 4D-CT scan techniques in multicenter phase III trial of surgery versus stereotactic radiotherapy (radiosurgery or surgery for operable early stage (stage 1A) non-small-cell lung cancer [ROSEL] study). International Journal of Radiation Oncology Biology	4	53	
277	Physics, <b>2011</b> , 80, 918-27 Improving target delineation on 4-dimensional CT scans in stage I NSCLC using a deformable registration tool. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 96, 67-72	5.3	53	
276	Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies. <i>Journal of Thoracic Disease</i> , <b>2011</b> , 3, 189-96	2.6	51	
275	Motion analysis of 100 mediastinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 1092-9	4	50	
274	Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 239-44	4.9	49	
273	When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis. <i>Chest</i> , <b>2014</b> , 146, 1021-1028	5.3	49	
272	Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. <i>Cancer</i> , <b>2009</b> , 115, 587-94	6.4	49	
271	Is adaptive treatment planning required for stereotactic radiotherapy of stage I non-small-cell lung cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 67, 1370-4	4	48	

270	Renal mobility during uncoached quiet respiration: an analysis of 4DCT scans. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 799-803	4	48
269	Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung canceran analysis of data generated using @low@CT scans. <i>Radiotherapy and Oncology</i> , <b>2001</b> , 61, 93-9	5.3	48
268	An analysis of anatomic landmark mobility and setup deviations in radiotherapy for lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 43, 827-32	4	48
267	PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung	4.9	47
266	Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, e10-1	2.2	47
265	Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 186-194	4 <sup>4</sup>	46
264	Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e104-8	2.2	46
263	Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 117, 64-70	5.3	45
262	Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 95-9	5.3	45
261	Patterns of Disease Recurrence after SABR for Early Stage Non-Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1195-200	8.9	45
260	A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. <i>Radiation Oncology</i> , <b>2006</b> , 1, 8	4.2	45
259	Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1994</b> , 29, 379-82	4	45
258	Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. <i>Lung Cancer</i> , <b>2017</b> , 108, 150-153	5.9	44
257	Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. <i>Oncologist</i> , <b>2008</b> , 13, 309-19	5.7	43
256	Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 426-433	4	43
255	Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , <b>2011</b> , 23, 133-9	4.2	42
254	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101308	2.2	42
253	Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 933-941	4	40

# (2014-2013)

252	Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes. <i>Acta Oncolgica</i> , <b>2013</b> , 52, 910-8	3.2	40	
251	Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 99, 161-5	5.3	40	
250	Stage I non-small cell lung cancer (NSCLC) in patients aged 75 years and older: does age determine survival after radical treatment?. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 818-24	8.9	40	
249	A new approach to quantifying lung damage after stereotactic body radiation therapy. <i>Acta Oncolgica</i> , <b>2011</b> , 50, 509-17	3.2	38	
248	Radiotherapy for lung cancer: clinical impact of recent technical advances. <i>Lung Cancer</i> , <b>2009</b> , 64, 1-8	5.9	37	
247	Impact of the calculation resolution of AAA for small fields and RapidArc treatment plans. <i>Medical Physics</i> , <b>2011</b> , 38, 4471-9	4.4	36	
246	Evaluation of four-dimensional computed tomography-based intensity-modulated and respiratory-gated radiotherapy techniques for pancreatic carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, 1215-20	4	36	
245	Critical review of PET-CT for radiotherapy planning in lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2005</b> , 56, 345-51	7	36	
244	Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, e141-e149	4.9	35	
243	Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. <i>Annals of Oncology</i> , <b>2011</b> , 22, 132-138	10.3	35	
242	Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1997</b> , 40, 1-10	3.5	35	
241	Clinical application of a novel hybrid intensity-modulated radiotherapy technique for stage III lung cancer and dosimetric comparison with four other techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, e297-303	4	34	
240	A four-dimensional CT-based evaluation of techniques for gastric irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, 903-9	4	34	
239	Defining target volumes for non-small cell lung carcinoma. <i>Seminars in Radiation Oncology</i> , <b>2004</b> , 14, 308-14	5.5	34	
238	Volumetric modulated arc therapy for advanced pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , <b>2010</b> , 186, 382-7	4.3	33	
237	Impact of audio-coaching on the position of lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 71, 1118-23	4	33	
236	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 94, 612-20	4	32	
235	High-dose, conventionally fractionated thoracic reirradiation for lung tumors. <i>Lung Cancer</i> , <b>2014</b> , 83, 356-62	5.9	31	

234	Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 974-982	8.9	30
233	An analysis of patient positioning during stereotactic lung radiotherapy performed without rigid external immobilization. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 104, 28-32	5.3	30
232	Can mediastinal nodal mobility explain the low yield rates for transbronchial needle aspiration without real-time imaging?. <i>Chest</i> , <b>2007</b> , 131, 1783-7	5.3	30
231	Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 144, 46-52	5.3	30
230	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1183-1209	8.9	29
229	Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 107, 403-8	5.3	29
228	A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 553-558	10.3	29
227	Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review. <i>Radiation Oncology</i> , <b>2020</b> , 15, 214	4.2	29
226	Radiotherapy for extensive stage small-cell lung cancer - Authors Oreply. Lancet, The, 2015, 385, 1292-3	40	28
225	Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 107, 270-278	4	28
224	Markerless tracking of small lung tumors for stereotactic radiotherapy. <i>Medical Physics</i> , <b>2015</b> , 42, 1640-	<b>52</b> .4	28
223	A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study. <i>BMC Cancer</i> , <b>2015</b> , 15, 959	4.8	27
222	Imaging for stereotactic spine radiotherapy: clinical considerations. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 321-30	4	27
221	Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , <b>2020</b> , 14, 17-23	3.1	26
220	Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. <i>Practical Radiation Oncology</i> , <b>2018</b> , 8, e71-e78	2.8	26
219	Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 1-5	4.9	26
218	Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer. <i>Lung Cancer</i> , <b>2011</b> , 74, 451-6	5.9	26
217	Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. <i>Radiation Oncology</i> , <b>2007</b> , 2, 2	4.2	26

### (2019-2007)

216	chemoradiation for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 912-5	8.9	26
215	Reproducibility of target volumes generated using uncoached 4-dimensional CT scans for peripheral lung cancer. <i>Radiation Oncology</i> , <b>2006</b> , 1, 43	4.2	26
214	Color intensity projections: a rapid approach for evaluating four-dimensional CT scans in treatment planning. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 954-61	4	26
213	The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. <i>Cancer Research and Treatment</i> , <b>2011</b> , 43, 75-82	5.2	26
212	Differences between pulmonologists, thoracic surgeons and radiation oncologists in deciding on the treatment of stage I non-small cell lung cancer: A binary choice experiment. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 115, 361-6	5.3	25
211	Defining target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional 18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography. <i>Clinical Oncology</i> , <b>2012</b> , 24, e71-80	2.8	25
210	Radiotherapy in small-cell lung cancer: lessons learned and future directions. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 998-1003	4	25
209	What margins are necessary for incorporating mediastinal nodal mobility into involved-field radiotherapy for lung cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 53, 121	1 <sup>4</sup> 5	25
208	Patient-reported Outcome Measurements on the Tolerance of Magnetic Resonance Imaging-guided Radiation Therapy. <i>Cureus</i> , <b>2018</b> , 10, e2236	1.2	25
207	Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 82-90	4	24
206	The MARS feasibility trial: conclusions not supported by data [AuthorsOeply. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 1094-1095	21.7	24
205	Comments on Gingle-Arc IMRT?O <i>Physics in Medicine and Biology</i> , <b>2009</b> , 54, L31-4; author reply L35-6	3.8	24
204	Analysis of reproducibility of respiration-triggered gated radiotherapy for lung tumors. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 87, 59-64	5.3	24
203	Evaluating mobility for radiotherapy planning of lung tumors: a comparison of virtual fluoroscopy and 4DCT. <i>Lung Cancer</i> , <b>2006</b> , 53, 31-7	5.9	24
202	Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 1092-7	4	23
201	Analysis of carina position as surrogate marker for delivering phase-gated radiotherapy.  International Journal of Radiation Oncology Biology Physics, 2008, 71, 1111-7	4	23
200	Procedures for high precision setup verification and correction of lung cancer patients using CT-simulation and digitally reconstructed radiographs (DRR). <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 55, 804-10	4	23
199	Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 132, 16-22	5.3	23

198	Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 566-72	8.9	22
197	Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixed-beam versus arc delivery techniques. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 77-81	5-3	22
196	Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1271-5	8.9	22
195	An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer. <i>Lung Cancer</i> , <b>2001</b> , 32, 145-53	5.9	22
194	Dosimetric impact of intrafraction motion during RapidArc stereotactic vertebral radiation therapy using flattened and flattening filter-free beams. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 86, 420-5	4	21
193	Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada. <i>Oncologist</i> , <b>2014</b> , 19, 880-5	5.7	21
192	Malignant pineal teratomas: a report on three patients and the case for craniospinal irradiation following chemotherapy. <i>Radiotherapy and Oncology</i> , <b>1991</b> , 22, 209-12	5.3	21
191	Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes. <i>Journal of Thoracic Disease</i> , <b>2013</b> , 5, 116-22	2.6	21
190	Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 943-947	4	20
189	Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. <i>European Urology Oncology</i> , <b>2021</b> , 4, 628	3-634	20
188	Second primary lung cancers following a diagnosis of primary head and neck cancer. <i>Lung Cancer</i> , <b>2015</b> , 88, 94-9	5.9	19
187	Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy. <i>Journal of Medical Imaging</i> , <b>2015</b> , 2, 041010	2.6	19
186	Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy. <i>Radiation Oncology</i> , <b>2011</b> , 6, 74	4.2	19
185	Stereotactic radiotherapy for stage I lung cancer: current results and new developments. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , <b>2010</b> , 14, 115-8	1.3	19
184	Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 1050-3	8.9	19
183	Indications and limitations of radiotherapy in malignant pleural mesothelioma. <i>Current Opinion in Oncology</i> , <b>2003</b> , 15, 144-7	4.2	19
182	Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer. <i>Radiation Oncology</i> , <b>2016</b> , 11, 131	4.2	19
181	Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e84-e88	4.9	18

180	Comparing rigid and deformable dose registration for high dose thoracic re-irradiation. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 323-6	5.3	18	
179	Use of CD-ROM-based tool for analyzing contouring variations in involved-field radiotherapy for Stage III NSCLC. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 63, 334-9	4	17	
178	Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 176-189	8.9	17	
177	Trimodality therapy for superior sulcus tumours: evolution and evaluation of a treatment protocol. <i>European Journal of Surgical Oncology</i> , <b>2013</b> , 39, 197-203	3.6	16	
176	Time for reappraisal of extracranial treatment options? Synchronous brain metastases from nonsmall cell lung cancer. <i>Cancer</i> , <b>2011</b> , 117, 597-605	6.4	16	
175	Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 142, 217-223	5.3	16	
174	Usage of Prophylactic Cranial Irradiation in Elderly Patients With Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e263-e267	4.9	16	
173	Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 689-698	8.9	15	
172	Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 927-934	4	15	
171	Beam intensity modulation for penumbra enhancement in the treatment of lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 44, 449-54	4	15	
170	A Primer on Interstitial Lung Disease and Thoracic Radiation. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 90	2 <del>9</del> 93	14	
169	Propensity-score matched pair comparison of whole brain with simultaneous in-field boost radiotherapy and stereotactic radiosurgery. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 206-9	5.3	14	
168	Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2013</b> , 80, 62-7	5.9	14	
167	Curative radiotherapy for a second primary lung cancer arising after pneumonectomy techniques and results. <i>Radiotherapy and Oncology</i> , <b>2002</b> , 62, 21-5	5.3	14	
166	Can errors in reconstructing pre-chemotherapy target volumes contribute to the inferiority of sequential chemoradiation in stage III non-small cell lung cancer (NSCLC)?. <i>Lung Cancer</i> , <b>2002</b> , 38, 297-3	o₹·9	14	
165	Nasal peripheral T-cell lymphoma: a 20-year review of cases treated in Scotland. <i>Clinical Oncology</i> , <b>1992</b> , 4, 96-100	2.8	14	
164	New techniques for assessing response after hypofractionated radiotherapy for lung cancer. Journal of Thoracic Disease, <b>2014</b> , 6, 375-86	2.6	14	
163	Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis. <i>International Journal of Radiation Opening Biology Physics</i> <b>2015</b> , 91, 133-9	4	13	

162	Systematic review of brain metastases prognostic indices. <i>Practical Radiation Oncology</i> , <b>2013</b> , 3, 101-6	2.8	13
161	Surgery for early-stage lung cancer: post-operative 30-day versus 90-day mortality and patient-centred care. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 675-7	7.5	13
160	Digital tomosynthesis (DTS) for verification of target position in early stage lung cancer patients. <i>Medical Physics</i> , <b>2013</b> , 40, 091904	4.4	13
159	Brachytherapy for recurrent head and neck cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>1999</b> , 13, 531-42	3.1	13
158	Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial		13
157	Treatment recommendations by clinicians in stage I non-small cell lung cancer: A study of factors that influence the likelihood of accounting for the patient@preference. <i>Patient Education and Counseling</i> , <b>2016</b> , 99, 1808-1813	3.1	13
156	A statistical comparison of prognostic index systems for brain metastases after stereotactic radiosurgery or fractionated stereotactic radiation therapy. <i>Clinical Oncology</i> , <b>2013</b> , 25, 227-35	2.8	12
155	Verifying 4D gated radiotherapy using time-integrated electronic portal imaging: a phantom and clinical study. <i>Radiation Oncology</i> , <b>2007</b> , 2, 32	4.2	12
154	A CT-assisted method of dosimetry in brachytherapy of lung cancer. Rotterdam Oncological Thoracic Study Group. <i>Radiotherapy and Oncology</i> , <b>2000</b> , 55, 75-80	5.3	12
153	Should regional ventilation function be considered during radiation treatment planning to prevent radiation-induced complications?. <i>Medical Physics</i> , <b>2016</b> , 43, 5072	4.4	12
152	Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 855-862	8.9	11
151	Stereotactic ablative radiation therapy for subcentimeter lung tumors: clinical, dosimetric, and image guidance considerations. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 90, 843-9	4	11
150	Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function. <i>Lung Cancer</i> , <b>2014</b> , 85, 218-23	5.9	11
149	Investigating strategies to reduce toxicity in stereotactic ablative radiotherapy for central lung tumors. <i>Acta Oncolgica</i> , <b>2014</b> , 53, 330-5	3.2	11
148	A brief report of 10-year trends in the use of stereotactic lung radiotherapy at a dutch academic medical center. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 114-7	8.9	11
147	Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies. <i>Lung Cancer</i> , <b>2010</b> , 69, 302-6	5.9	11
146	Stereotactic radiotherapy for centrally located early-stage lung tumors. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 464; author reply 465	2.2	11
145	The role of radiotherapy in non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16 Suppl 2, ii223-8	10.3	11

### (2021-2019)

144	End-to-end empirical validation of dose accumulation in MRI-guided adaptive radiotherapy for prostate cancer using an anthropomorphic deformable pelvis phantom. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 141, 200-207	5.3	10
143	Improving radiotherapy planning for large volume lung cancer: a dosimetric comparison between hybrid-IMRT and RapidArc. <i>Acta Oncolgica</i> , <b>2015</b> , 54, 427-32	3.2	10
142	Comparison of radiation-induced normal lung tissue density changes for patients from multiple institutions receiving conventional or hypofractionated treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 626-32	4	10
141	A brief report on outcomes of stereotactic ablative radiotherapy for a second primary lung cancer: evidence in support of routine CT surveillance. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1222-5	8.9	10
140	A novel simple approach for incorporation of respiratory motion in stereotactic treatments of lung tumors. <i>Radiotherapy and Oncology</i> , <b>2010</b> , 97, 443-8	5.3	10
139	An evaluation of two internal surrogates for determining the three-dimensional position of peripheral lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 623-9	4	10
138	A treatment planning study evaluating a @imultaneous integrated boost@echnique for accelerated radiotherapy of stage III non-small cell lung cancer. <i>Lung Cancer</i> , <b>2004</b> , 45, 57-65	5.9	10
137	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 1479-148	39 <sup>5.4</sup>	10
136	The Head Start Effect: Will Acute and Delayed Postoperative Mortality Lead to Improved Survival with Stereotactic Body Radiation Therapy for Operable Stage I Non-Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1749-1751	2.2	9
135	High-dose conventional thoracic re-irradiation for lung cancer: updated results. <i>Lung Cancer</i> , <b>2015</b> , 88, 235-6	5.9	9
134	Communicating cancer treatment information using the Web: utilizing the patient@perspective in website development. <i>BMC Medical Informatics and Decision Making</i> , <b>2014</b> , 14, 116	3.6	9
133	Systematic review of fractionated brain metastases radiotherapy. <i>Journal of Radiation Oncology</i> , <b>2014</b> , 3, 29-41	0.7	9
132	Use of megavoltage cine-images for studying intra-thoracic motion during radiotherapy for locally advanced lung cancer. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 99, 155-60	5.3	9
131	Reply: Patterns of nodal recurrence after omission of elective nodal irradiation for limited-stage small-cell lung cancer. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 276-276	8.7	9
130	Involved-node radiotherapy to the mediastinum. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 82, 108-9; author reply 109-10	5.3	9
129	Cigarette smoking is a risk factor for bleomycin-induced pulmonary toxicity. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 2084	7.5	9
128	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , <b>2021</b> , 151, 30-38	5.9	9
127	Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. <i>Oncologist</i> , <b>2021</b> , 26, e306-e315	5.7	9

126	Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. <i>ESMO Open</i> , <b>2021</b> , 6, 100244	6	9
125	Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy. <i>Acta Oncolgica</i> , <b>2017</b> , 56, 548-554	3.2	8
124	Surgery versus SABR for resectable non-small-cell lung cancer - Authors@eply. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e374-5	21.7	8
123	Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2196	10.3	8
122	Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010. <i>Acta Oncolgica</i> , <b>2014</b> , 53, 316-23	3.2	8
121	Conventional 3D staging PET/CT in CT simulation for lung cancer: impact of rigid and deformable target volume alignments for radiotherapy treatment planning. <i>British Journal of Radiology</i> , <b>2011</b> , 84, 919-29	3.4	8
<b>12</b> 0	Inferring positions of tumor and nodes in Stage III lung cancer from multiple anatomical surrogates using four-dimensional computed tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 77, 1553-60	4	8
119	Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5cm. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 103, 259-267	4	8
118	The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1183-1188	8.9	8
117	Stereotactic Ablative Radiotherapy Induces Peripheral T-Cell Activation in Patients with Early-Stage Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1224-1227	10.2	7
116	Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 488-496	8.9	7
115	Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 127, 233-238	5.3	7
114	Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2009</b> , 36, 1052-7	3	7
113	Lung cancer: intensity-modulated radiation therapy, four-dimensional imaging and mobility management. <i>Frontiers of Radiation Therapy and Oncology</i> , <b>2007</b> , 40, 239-252		7
112	Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma. <i>Lung Cancer</i> , <b>2004</b> , 45 Suppl 1, S93-6	5.9	7
111	Palliation of malignant phaeochromocytoma with combination chemotherapy. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1006-7	7.5	7
110	Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC)	2.2	7
109	Journal of Clinical Oncology, <b>2015</b> , 33, 7506-7506  A Phase II Study of Induction Therapy with Carboplatin and Gemcitabine among Patients with Locally Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 532-536	8.9	7

108	The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
107	Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 109, 1176-1184	4	7
106	Surgical Treatment of Complications After High-Dose Chemoradiotherapy for Lung Cancer. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 104, 436-442	2.7	6
105	A Population-Based Study of Outcomes in Surgically Resected T3N0 Non-Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 459-467	8.9	6
104	Stereotactic ablative radiotherapy in patients with early-stage non-small cell lung cancer and co-existing interstitial lung disease. <i>Acta Oncolgica</i> , <b>2020</b> , 59, 569-573	3.2	6
103	Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1755-1765	8.9	6
102	Feasibility of using anatomical surrogates for predicting the position of lung tumours. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 102, 287-9	5.3	6
101	Pulmonary atelectasis after stereotactic ablative radiotherapy for a central lung tumor. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, e94-5	8.9	6
100	Reply: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 1138-9	8.9	6
99	Mucosal dose prescription in endobronchial brachytherapy: a study based on CT-dosimetry. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2000</b> , 46, 1051-9	4	6
98	Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. <i>BMC Cancer</i> , <b>2020</b> , 20, 764	4.8	6
97	Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study. <i>Anticancer Research</i> , <b>2010</b> , 30, 4237-43	2.3	6
96	Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse	3.5	5
	and human plasma for pharmacokinetically guided dose escalation. Cancer Chemotherapy and	<i>J</i> - <i>J</i>	
95	Pharmacology, 1995, 36, 266-70  An analysis of planned versus delivered airway doses during stereotactic lung radiotherapy for central tumors. Acta Oncologica, 2016, 55, 934-7	3.2	5
95 94	Pharmacology, 1995, 36, 266-70 An analysis of planned versus delivered airway doses during stereotactic lung radiotherapy for		5
	Pharmacology, 1995, 36, 266-70 An analysis of planned versus delivered airway doses during stereotactic lung radiotherapy for central tumors. Acta Oncolgica, 2016, 55, 934-7  Analysis of components of variance determining probability of setup errors in CBCT-guided	3.2	
94	An analysis of planned versus delivered airway doses during stereotactic lung radiotherapy for central tumors. <i>Acta Oncolgica</i> , <b>2016</b> , 55, 934-7  Analysis of components of variance determining probability of setup errors in CBCT-guided stereotactic radiotherapy of lung tumors. <i>Medical Physics</i> , <b>2017</b> , 44, 382-388  Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in	3.2	4

90	Stereotactic lung radiotherapy: do we need fiducial markers?. <i>Annals of Thoracic Surgery</i> , <b>2011</b> , 91, 335-6; author reply 336	2.7	4
89	B5-04: Clinical results and toxicity after 4-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S348	8.9	4
88	Staging nodal disease in non-small cell lung cancer: implications for radiation therapy. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 585-7	8.9	4
87	Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR 4233) and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1995</b> , 31, 209-10	4	4
86	The diagnosis and treatment of nasal lymphoma, an important cause of upper respiratory tract destruction. <i>Clinical Otolaryngology</i> , <b>1992</b> , 17, 563-6	1.8	4
85	Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7009-7009	2.2	4
84	Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III Non-Small-Cell Lung Cancer: Is There an Impact on Radiation Pneumonitis Rates?. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2927	2.2	3
83	Stereotactic body radiotherapy for central lung tumours. <i>British Journal of Radiology</i> , <b>2015</b> , 88, 2015041	<b>9</b> .4	3
82	Diagnostic challenges in survivors of early stage lung cancer. <i>Lung Cancer</i> , <b>2015</b> , 90, 212-6	5.9	3
81	Bowel-sparing intensity-modulated radiotherapy (IMRT) for palliation of large-volume pelvic bone metastases: rationale, technique and clinical implementation. <i>Acta Oncolgica</i> , <b>2013</b> , 52, 877-80	3.2	3
80	B5-06: Mature results of PulmonArt: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (pts) with stage III	8.9	3
79	non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S349-S350 Incorporating lung tumor mobility in radiotherapy planning. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 52, 1142-3; author reply 1144	4	3
78	The history of radiotherapy in The Netherlands. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1996</b> , 35, 615-22	4	3
77	Changes in gastric anatomy after delivery of breath-hold MR-guided SABR for adrenal metastases. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 152, 26-29	5.3	3
76	Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands. <i>Clinical Oncology</i> , <b>2018</b> , 30, 17-22	2.8	3
75	In Reply to Cobben and Jager. International Journal of Radiation Oncology Biology Physics, <b>2015</b> , 92, 700-	-14	2
74	Points to consider regarding the SABR-COMET trial - Authors Creply. Lancet, The, 2020, 395, e20	40	2
73	Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - AuthorsOeply. Lancet Oncology, The, <b>2016</b> , 17, e42-e43	21.7	2

### (2021-2013)

72	Non-coplanar volumetric modulated arc therapy for irradiation of paranasal sinus tumors: in response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and	4.4	2
71	radiotherapy or (chemo)radiation. Oral Oncol 2012;48(9):905-11. <i>Oral Oncology</i> , <b>2013</b> , 49, e8  Treatment for high-risk patients with early-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 377	2.2	2
70	Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer: in regards to Register et al. Int J Radiat Oncol Biol Phys 2011;80:1015-1022. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 492; author reply 492	4	2
69	In reply to Zagar and Marks. International Journal of Radiation Oncology Biology Physics, <b>2012</b> , 84, 305-6	4	2
68	Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer. <i>Acta Oncolgica</i> , <b>2013</b> , 52, 676-8	3.2	2
67	Surveillance with computed tomography after curative treatment of early-stage lung cancer. Journal of Clinical Oncology, <b>2013</b> , 31, 3607	2.2	2
66	Radiation oncology: overview and recent advances. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , <b>2010</b> , 40, 136-43; quiz 143-4	0.9	2
65	Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable Stage I-II non-small-cell lung cancer. In reply to Dr. Xiao et al. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 318; author reply 318	4	2
64	Novel tools in radiotherapy. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 7, vii294-9	10.3	2
63	Blinded assessment of radiological changes after stereotactic ablative radiotherapy (SABR) for early-stage lung cancer: Local recurrences versus fibrosis <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 7520-7	520	2
62	A1-02: A need to standardize post-operative radiotherapy (PORT) fields used for non-small cell lung cancer (NSCLC): analysis of an international dummy-run study. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S308-S309	8.9	2
61	The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 156, 223-	238	2
60	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 1165-1184	3.6	2
59	Developments in radiation techniques for thoracic malignancies. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	2
58	Can the probability of radiation esophagitis be reduced without compromising lung tumor control: A radiobiological modeling study. <i>Acta Oncolgica</i> , <b>2016</b> , 55, 926-30	3.2	2
57	Defining the role of radiofrequency ablation and stereotactic ablative radiotherapy in patients with high-risk, early-stage non-small cell lung cancer. <i>Cancer</i> , <b>2016</b> , 122, 322-3	6.4	2
56	Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. <i>Lung Cancer</i> , <b>2021</b> , 152, 149-156	5.9	2
55	Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 163, 14-20	) <sup>5.3</sup>	2

54	Radical-Intent Treatment of Lung Cancer after Prior Thoracic Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, e26-e27	8.9	1
53	Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1761-1767	2.5	1
52	Parenchymal lung changes on computed tomography after stereotactic radiotherapy using high dose rate flattening filter free beams. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 114, 357-60	5.3	1
51	Treatment and survival of second primary early-stage lung cancer, following treatment of head and neck cancer in the Netherlands. <i>Lung Cancer</i> , <b>2016</b> , 94, 54-60	5.9	1
50	Early prediction of lung cancer recurrence after stereotactic radiotherapy using second order texture statistics <b>2014</b> ,		1
49	Texture analysis of automatic graph cuts segmentations for detection of lung cancer recurrence after stereotactic radiotherapy <b>2015</b> ,		1
48	CT image feature analysis in distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a preliminary study <b>2013</b> ,		1
47	Color Intensity Projections: A Simple Way to Display Changes in Astronomical Images. <i>Publications of the Astronomical Society of the Pacific</i> , <b>2007</b> , 119, 523-526	5	1
46	Critical factors for patient management. <i>Lung Cancer</i> , <b>2003</b> , 42 Suppl 1, S7-8	5.9	1
45	Regarding scoring of radiation pneumonitis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2000</b> , 48, 609	4	1
44	Lung abscess: a fatal complication of treatment for testicular teratoma. Clinical Oncology, 1991, 3, 345-	72.8	1
43	Overcoming tumour radiation resistance resulting from acute hypoxia. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 2085-6	7.5	1
42	Failure of palliative radiotherapy in high-grade angiosarcoma of bone. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1934	7.5	1
41	The radiobiological basis of concomitant cisplatin and radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1993</b> , 27, 483-4	4	1
40	Complication probability for radiation pneumonitis (RP) after stereotactic body radiotherapy (SBRT). <i>Journal of Radiosurgery and SBRT</i> , <b>2013</b> , 2, 99-104	0.4	1
39	The elusive pursuit of progress in limited stage small-cell lung cancer. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 290-291	21.7	1
38	Age-related treatment patterns for stage I NSCLC in three European countries. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 1214-1219	3.6	1
37	Finding the Goldilocks zone in neoadjuvant radioimmunotherapy. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 545-546	19.4	1

# (2003-2016)

36	Treatment of Stage IIIA Non-Small-Cell Lung Cancer: Charting the Next Steps. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, 609-10	3.1	1
35	X-change symposium: status and future of modern radiation oncology-from technology to biology. <i>Radiation Oncology</i> , <b>2021</b> , 16, 27	4.2	1
34	SBRT for pancreatic cancer: In regard of Bohoudi et al. Radiotherapy and Oncology, 2018, 127, 511-512	5.3	1
33	The Nordic-HILUS Trial: Ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, e79-e80	8.9	1
32	Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases. <i>Physics and Imaging in Radiation Oncology</i> , <b>2021</b> , 20, 1-4	3.1	1
31	The interaction of cisplatin and radiotherapy. <i>Clinical Oncology</i> , <b>1993</b> , 5, 191-2	2.8	O
30	SABR Given Thoughtfully. International Journal of Radiation Oncology Biology Physics, 2017, 99, 766	4	
29	Stage I Nonsmall Cell Lung Cancer and Oligometastatic Disease <b>2018</b> , 342-354.e4		
28	Computed tomography surveillance of patients with resected lung cancer: Recurrence or second primary lung cancer?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2014</b> , 147, 1715	1.5	
27	What causes early mortality in patients with large tumors receiving radical chemo-radiotherapy for non-small cell lung cancer? In response to Ball et al. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 109, 179-80	5.3	
26	Are the reported clinical outcomes with stereotactic ablative radiotherapy generalizable?. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 995-6	8.9	
25	Four-dimensional Radiation Therapy for Non-Small Cell Lung Cancer: A Clinical Perspective. <i>Medical Radiology</i> , <b>2011</b> , 157-172	0.2	
24	Reflections on the 14th World Conference on Lung Cancer: A European Perspective. <i>Oncologist</i> , <b>2012</b> , 17, 463-465	5.7	
23	Treatment of peripheral lung tumors arising after a prior pneumonectomy. <i>Chest</i> , <b>2012</b> , 142, 263	5.3	
22	In Reply to Dr. Bauman. International Journal of Radiation Oncology Biology Physics, 2010, 78, 965	4	
21	CT-guided pulmonary radiofrequency ablation. <i>Radiology</i> , <b>2008</b> , 246, 334-5; author reply 334-5	20.5	
20	PL3-02: Advances in radiation oncology. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S146-S148	8.9	
19	In regard to Rosenman et al., high-dose conformal radiotherapy for treatment of stage III A/B non-small-cell lung cancer: technical issues and results of a phase I/II trial. IJROBP 2002;54:348-356. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2003</b> , 55, 1458-9; author reply 1459-60	4	

18	Reply to "Radiation pneumonitis and docetaxel". <i>Lung Cancer</i> , <b>2004</b> , 43, 117-8; author reply 119-20	5.9
17	Optimum management of pineal germ cell tumours. <i>Clinical Oncology</i> , <b>1991</b> , 3, 301	2.8
16	Diagnosis and treatment of lymphomatoid granulomatosis. <i>Postgraduate Medical Journal</i> , <b>1992</b> , 68, 84	11-2
15	Primary intracranial germ cell tumours (GCT) fail to highlight important aspects of the current management of this condition. <i>Journal of Neuro-Oncology</i> , <b>1992</b> , 14, 289-90	4.8
14	Letter in response to paper by Abratt et al., Cancer Chemother Pharmacol (1992) 30: 495. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1993</b> , 31, 500-1	3.5
13	Target Volumes in Non-Small Cell Lung Cancer <b>2005</b> , 97-110	
12	Imaging for high-precision thoracic radiotherapy. Journal of Thoracic Disease, 2012, 4, 106-8	2.6
11	Exploring controversies in lung cancer using structured pro-con debates. <i>Translational Lung Cancer Research</i> , <b>2015</b> , 4, 475	4-4
10	An evaluation of websites providing patient information on stereotactic body radiation therapy (SBRT) for stage I lung cancer in three Western European countries. <i>Journal of Radiosurgery and SBRT</i> , <b>2012</b> , 1, 303-315	0.4
	• • •	
9	Anatomical and Biological Imaging <b>2005</b> , 109-130	
9		2.2
	Anatomical and Biological Imaging <b>2005</b> , 109-130  Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer <i>Journal</i>	2.2
	Anatomical and Biological Imaging 2005, 109-130  Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer <i>Journal of Clinical Oncology</i> , 2014, 32, 7502-7502  When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung	
8	Anatomical and Biological Imaging 2005, 109-130  Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer <i>Journal of Clinical Oncology</i> , 2014, 32, 7502-7502  When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis <i>Journal of Clinical Oncology</i> , 2014, 32, 7534-7534  Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous	2.2
8 7 6	Anatomical and Biological Imaging 2005, 109-130  Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer <i>Journal of Clinical Oncology</i> , 2014, 32, 7502-7502  When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis <i>Journal of Clinical Oncology</i> , 2014, 32, 7534-7534  Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC) <i>Journal of Clinical Oncology</i> , 2016, 34, 8529-8529	2.2
8 7 6	Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7502-7502  When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7534-7534  Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC) <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 8529-8529  Curative Radiotherapy in Patients Inoperable for Medical Reasons <b>2013</b> , 151-162	2.2
8 7 6 5	Anatomical and Biological Imaging 2005, 109-130  Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer <i>Journal of Clinical Oncology</i> , 2014, 32, 7502-7502  When is a pathologic diagnosis preferred before stereotactic ablative radiotherapy for stage I lung cancer? A decision analysis <i>Journal of Clinical Oncology</i> , 2014, 32, 7534-7534  Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC) <i>Journal of Clinical Oncology</i> , 2016, 34, 8529-8529  Curative Radiotherapy in Patients Inoperable for Medical Reasons 2013, 151-162  4-Dimensional Imaging for Radiation Oncology: A Clinical Perspective 2013, 251-284  Testing the Effects of Modality and Narration Style on PatientsOnformation Use in a Lung Cancer	2.2